CAR-T Cell therapy market size will touch US$ 8 BN by 2028: Credence Research Inc.

The latest market report published by Credence Research, Inc. “CAR T-Cell Therapy Market - Growth, Future Prospects, Competitive Analysis, 2018 - 2026,” the global CAR-T cell therapy market was valued at US$ 72.0 Mn in 2017 expanding at a CAGR of 51.1% from 2018 to 2026.

"Despite great progress in recent years, around 10% of children with childhood leukemia, the most common childhood cancer, still die from it, with the percentage even greater in adolescents and young adults with the disease. CAR T-cell therapy involves taking healthy T-cells from a patient's blood, genetically modifying them to target their leukemia cells and injecting them back into the circulation. The method has been shown in trials to have hugely impressive results in these children, achieving FDA-approval last year, and is now offered in a number of U.S. pediatric cancer treatment centers."

"CAR T-cells are very promising and have produced really exciting early results. It's great to see companies prioritizing launches of medicines in the U.K.," said Rose Gray, Policy Manager at Cancer Research UK, the world's largest independent cancer charity.- Forbes

Market Insights

The CAR T-cell therapy market is driven by factors such as rising prevalence of cancer, growing research in the immune-oncology, and massive funding from government health institution and pharma giants in CAR-T cell therapy development. The diagnosis of acute ALL is very ambiguous as the symptoms overlap with Non-Hodgkin lymphoma. World Health Organization guidelines have postulated that acute lymphocytic leukemia can be prevented up to a certain extent by prohibiting the exposure to radiation, chemical, viral infection, cigarette smoking and prolonged exposure to gasoline and electromagnetic fields. The traditional approach adopted for the treatment of leukemia was blood transfusion to increase the count of healthy blood cells, antibiotics used to curb the spread of infection and chemotherapy to kill the leukemia cells present in the bone marrow. However, advances in the cell therapy and gene therapy has have rendered the development of oncology treatment by body’s own immune system. The FDA approved CAR T-cell therapy are Axicabtagene ciloleucel (Yescarta) and Tisagenleucel (Kymriah),). Currently CD19 antigens have been approved by USFDA for the treatment of relapsed b-cell acute lymphocytic leukemia. Whereas, there are more than 2,000 candidates in the clinical trials for different cancer indications.

Browse the full report CAR T-cell Therapy Market - Growth, Future Prospects, Competitive Analysis, 2018 – 2026 report at https://www.credenceresearch.com/report/car-t-cell-therapy-market

CD19 antigens as CAR T-cell therapy for the treatment of B cell acute lymphocytic leukemia and increasing number of children suffering with acute lymphocytic leukemia is responsible for the dominance of ALL. Geographically, North America dominated the CAR-T cell therapy market due to approval of two CAR T-cell therapy candidates in the region. Moreover, rising prevalence of relapsed acute lymphocytic leukemia and technological advancement in the screening of cancer drives the CAR T-cells therapy market. Moreover, the domicile of pharmaceutical companies pioneering in CAR-T cell therapy further increases the dominance of United States. Increasing geriatric population suffering with leukemia and government initiatives to fight cancer will result in the growth of CAR-T cell therapy in Europe and Asia Pacific. However, penetration of CAR-T cell therapy within low and middle income economies are primarily hampered owing to the unavailability of suitable healthcare infrastructure and the lack of disposable income for such premium priced therapeutic options. The major pharmaceutical players actively engaged in the CAR-T cell therapy market are Gilead Sciences, Inc., Bellicum Pharmaceuticals, Inc., Immune Therapeutics, Celgene Corporation, Cellectis, Kite Pharma, Eureka Therapeutics, Juno Therapeutics, Sorrento Therapeutics and Novartis AG among others.

Key Market Movements:

Rising prevalence of patients suffering with relapsed b cell acute lymphocytic leukemia
Proactive role adopted by regulatory agencies for the expedited approval of CAR T cell therapy
Promising pipeline for CAR T-cell therapy focusing on CD22, CD30 antigens for the treatment of non-Hodgkin’s lymphoma and acute myeloid leukemia respectively
Higher adoption of Immunotherapy for cancer treatment in North America and Europe contribute towards the growth of the market
Partnerships, collaboration and capital funding between pharmaceutical giants and budding biotechnology to increase research and development of immunotherapy for cancer treatment
ToC:

Chapter 1 Preface
1.1 Report Description
1.1.1 Study Purpose
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global CAR-T Cell Therapy Market Portraiture
2.2 Global CAR-T Cell Therapy Market, by Indication, 2017 vs 2026 (Value %)
2.3 Global CAR-T Cell Therapy Market, by Geography, 2017 vs 2026 (Value %)

Chapter 3 Global CAR-T Cell Therapy Market: Dynamics and Future Outlook
3.1 Overview
3.2 Market Drivers
3.2.1 Emerging Immuno-Oncology in Clinical Cancer Research
3.2.2 Rising Prevalence of Cancer
3.3 Challenges
3.3.1 High Cost of CAR-T Cell Therapy
3.4 Opportunities
3.4.1 Mergers and Acquisition in the CAR-T Cell Therapy Market
3.4.2 CAR-T Cell Therapy Beyond Cancer Treatment
3.5 Attractive Investment Proposition: Global CAR-T Cell Therapy Market, by Indication, 2018
3.6 Competitive Analysis: Global CAR-T Cell Therapy Market, 2017........

Request Sample on this research study: https://www.credenceresearch.com/sample-request/58970

Latest Reports:

https://www.credenceresearch.com/report/chronic-kidney-disease-ckd-drugs-market

https://www.credenceresearch.com/report/pulmonary-drug-delivery-devices-market

About Us
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we've manufactured a firm extraordinarily prepared to this task.

Media Contact
Company Name: Credence Research, Inc
Contact Person: Chris Smith, Global Sales Manager
Email: sales@credenceresearch.com
Phone: +1-800-361-8290
Address: 105 N 1st ST #429, SAN JOSE, CA 95103 US
City: SAN JOSE
State: California
Country: United States
Website: https://www.credenceresearch.com/report/car-t-cell-therapy-market

This release was published on openPR.